CRVO CervoMed Inc.
$2.57▲ +4.05%
Healthcare
Other
After hours
$2.63▲ +2.33%
Sep 11, 7:30 PM ET
Volume 233.5K
Avg Volume (10D) 187.9K
Key Metrics & Fundamentals
Market Cap
$38.86M
P/E Ratio
–
Div Yield
–%
52W Range
2.13 - 10.00
% vs 50 MA
-9.10%
% vs 200 MA
-43.14%
RSI-14
44.7
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.83
Free Cash Flow
-$6.92M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.68M
COGS
–
Operating Exp
$6.68M
Operating Income
-$6.68M
EBIT
-$6.68M
Pretax Income
-$6.57M
Net Income
-$6.57M
EPS (Diluted)
-0.64
Price & Volume History
Loading chart…
Recent News
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
GlobeNewswire · Sep 10, 2026 11:30 AM
CervoMed to Participate in September Investor Conferences
GlobeNewswire · Sep 8, 2026 11:30 AM
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 6, 2026 9:20 PM
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 5, 2026 1:00 PM
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · Aug 5, 2026 11:30 AM
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · Aug 4, 2026 9:15 AM
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · Jul 14, 2026 11:30 AM
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia
MT Newswires · Jul 9, 2026 12:06 PM
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
GlobeNewswire · Jul 9, 2026 11:30 AM
CervoMed Files for Resale of Common Shares
MT Newswires · Jul 6, 2026 9:39 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CRVO's money flow as a full page
Social Sentiment
Avg +0.70 · 4 posts
NewsDiscussionTradeCRVO
r/wallstreetbets · Mar 20, 2025
The post mentions a potential short squeeze, a generally positive signal for the stock.
positive
+0.60
DDPriceTarget$CRVO
r/wallstreetbets · Dec 13, 2024
The author expresses optimism about CRVO's potential and suggests a significant upside, indicating a bullish sentiment.
positive
+0.70
PriceTargetDDCRVO - Journey to $35
r/wallstreetbets · Dec 9, 2024
The user expresses confidence and encourages a 'YOLO' investment, indicating a bullish outlook.
positive
+0.70
DDNewsEarningsPriceTarget$CRVO is about to explode next week
r/wallstreetbets · Aug 9, 2024
The post expresses strong bullish sentiment regarding CRVO's stock performance and future earnings.
very_positive
+0.80
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.